clinical-trial-automation
(2)
Joshua Wang Is Building for the Part of AI That Has to Show Its Work
The Astraea co-founder left Stanford to automate clinical trial biometrics. His sharper insight is that in regulated AI, speed only matters when every decision can be reviewed.
Formation Bio
Formation Bio is a New York-based, AI-native pharmaceutical company that acquires and in-licenses clinical-stage drug candidates and runs them through a proprietary, technology-driven development platform to bring treatments to patients faster and at lower cost. Formerly known as TrialSpark, the company rebranded in December 2023 and raised a $372M Series D in June 2024 led by Andreessen Horowitz and Sanofi. It pairs in-house drug selection expertise with AI tools for trial design, recruitment, regulatory writing, and safety monitoring, and partnered with OpenAI and Sanofi to build purpose-built AI agents for drug development.